{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T17:14:46Z","timestamp":1649006086062},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,11,29]],"date-time":"2005-11-29T00:00:00Z","timestamp":1133222400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Dermatol"],"published-print":{"date-parts":[[2005,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Pathologists are often faced with the dilemma of whether to recommend continuation of methotrexate therapy for psoriasis within the context of an existing pro-fibrogenic risk factor, in this instance, patients with genetic hemochromatosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentations<\/jats:title>\n            <jats:p>We describe our experience with two male psoriatic patients (A and B) on long term methotrexate therapy (cumulative dose A = 1.56 gms and B = 7.88 gms) with hetero- (A) and homozygous (B) genetic hemochromatosis. These patients liver function were monitored with routine biochemical profiling; apart from mild perivenular fibrosis in one patient (B), significant liver fibrosis was not identified in either patient with multiple interval percutaneous liver biopsies; in the latter instance this patient (B) had an additional risk factor of partiality to alcohol.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>We conclude that methotrexate therapy is relatively safe in patients with genetic hemochromatosis, with no other risk factor, but caution that the risk of fibrosis be monitored, preferably by non-invasive techniques, or by liver biopsy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-5945-5-12","type":"journal-article","created":{"date-parts":[[2005,11,30]],"date-time":"2005-11-30T07:14:09Z","timestamp":1133334849000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A liver fibrosis cocktail? Psoriasis, methotrexate and genetic hemochromatosis"],"prefix":"10.1186","volume":"5","author":[{"given":"Joseph","family":"Mathew","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May Y","family":"Leong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Morley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alastair D","family":"Burt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,11,29]]},"reference":[{"key":"59_CR1","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/art.1780311202","volume":"31","author":"DJ Bjorkman","year":"1988","unstructured":"Bjorkman DJ, Hammond EH, Lee RG, Clegg DO, Tolman KG: Hepatic ultrastructure after methotrexate therapy for rheumatoid arthritis. Arthritis Rheum 1988, 31: 1465\u20131472.","journal-title":"Arthritis Rheum"},{"key":"59_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/0190-9622(93)70006-F","volume":"28","author":"C Nohlgard","year":"1993","unstructured":"Nohlgard C, Rubio CA, Kock Y, Hammar H: Liver fibrosis quantified by image analysis in methotrexate-treated patients with psoriasis. J Am Acad Dermatol 1993, 28: 40\u201345.","journal-title":"J Am Acad Dermatol"},{"key":"59_CR3","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3109\/15563659609013794","volume":"34","author":"K Jaskiewicz","year":"1996","unstructured":"Jaskiewicz K, Voigt H, Blakolmer K: Increased matrix proteins, collagen and transforming growth factor are early markers of hepatotoxicity in patients on long-term methotrexate therapy. J Toxicol Clin Toxicol 1996, 34: 301\u2013305.","journal-title":"J Toxicol Clin Toxicol"},{"key":"59_CR4","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1309\/5HR90TNC4Q4JRXWX","volume":"121","author":"P Hytiroglou","year":"2004","unstructured":"Hytiroglou P, Tobias H, Saxena R, Abramidou M, Papadimitriou CS, Theise ND: The canals of hering might represent a target of methotrexate hepatic toxicity. Am J Clin Pathol 2004, 121: 324\u2013329. 10.1309\/5HR9-0TNC-4Q4J-RXWX","journal-title":"Am J Clin Pathol"},{"key":"59_CR5","first-page":"511","volume":"85","author":"A Nyfors","year":"1977","unstructured":"Nyfors A: Liver biopsies from psoriatics related to methotrexate therapy. 3. Findings in post-methotrexate liver biopsies from 160 psoriatics. Acta Pathol Microbiol Scand [A] 1977, 85: 511\u2013518.","journal-title":"Acta Pathol Microbiol Scand [A]"},{"key":"59_CR6","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0002-9343(88)80019-6","volume":"85","author":"WJ Shergy","year":"1988","unstructured":"Shergy WJ, Polisson RP, Caldwell DS, Rice JR, Pisetsky DS, Allen NB: Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis. Am J Med 1988, 85: 771\u2013774.","journal-title":"Am J Med"},{"key":"59_CR7","first-page":"1730","volume":"95","author":"M Lemann","year":"2000","unstructured":"Lemann M, Zenjari T, Bouhnik Y, Cosnes J, Mesnard B, Rambaud JC, Modigliani R, Cortot A, Colombel JF: Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol 2000, 95: 1730\u20131734.","journal-title":"Am J Gastroenterol"},{"key":"59_CR8","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1111\/j.1572-0241.2000.03287.x","volume":"95","author":"HS Te","year":"2000","unstructured":"Te HS, Schiano TD, Kuan SF, Hanauer SB, Conjeevaram HS, Baker AL: Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000, 95: 3150\u20133156. 10.1111\/j.1572-0241.2000.03287.x","journal-title":"Am J Gastroenterol"},{"key":"59_CR9","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/j.1365-2133.1995.tb02754.x","volume":"133","author":"MJ Boffa","year":"1995","unstructured":"Boffa MJ, Chalmers RJ, Haboubi NY, Shomaf M, Mitchell DM: Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal. Br J Dermatol 1995, 133: 774\u2013778.","journal-title":"Br J Dermatol"},{"key":"59_CR10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1365-2230.1996.tb00142.x","volume":"21","author":"MJ Boffa","year":"1996","unstructured":"Boffa MJ, Chalmers RJ: Methotrexate for psoriasis. Clin Exp Dermatol 1996, 21: 399\u2013408.","journal-title":"Clin Exp Dermatol"},{"key":"59_CR11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1046\/j.1365-2036.2004.01819.x","volume":"19","author":"GP Aithal","year":"2004","unstructured":"Aithal GP, Haugk B, Das S, Card T, Burt AD, Record CO: Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified? Aliment Pharmacol Ther 2004, 19: 391\u2013399. 10.1046\/j.1365-2036.2004.01819.x","journal-title":"Aliment Pharmacol Ther"},{"key":"59_CR12","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/00007611-198605000-00005","volume":"79","author":"FS Reynolds","year":"1986","unstructured":"Reynolds FS, Lee WM: Hepatotoxicity after long-term methotrexate therapy. South Med J 1986, 79: 536\u2013539.","journal-title":"South Med J"},{"key":"59_CR13","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1001\/archderm.1980.01640280049016","volume":"116","author":"JK Robinson","year":"1980","unstructured":"Robinson JK, Baughman RD, Auerbach R, Cimis RJ: Methotrexate hepatotoxicity in psoriasis. Consideration of liver biopsies at regular intervals. Arch Dermatol 1980, 116: 413\u2013415. 10.1001\/archderm.116.4.413","journal-title":"Arch Dermatol"},{"key":"59_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/00000478-197709000-00005","volume":"1","author":"A Nyfors","year":"1977","unstructured":"Nyfors A, Poulsen H: Morphogenesis of fibrosis and cirrhosis in methotrexate-treated patients with psoriasis. Am J Surg Pathol 1977, 1: 235\u2013243.","journal-title":"Am J Surg Pathol"},{"key":"59_CR15","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1046\/j.1440-1746.2001.02644.x","volume":"16","author":"G Langman","year":"2001","unstructured":"Langman G, Hall PM, Todd G: Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol 2001, 16: 1395\u20131401. 10.1046\/j.1440-1746.2001.02644.x","journal-title":"J Gastroenterol Hepatol"},{"key":"59_CR16","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/0049-0172(92)90038-F","volume":"21","author":"JM Kremer","year":"1992","unstructured":"Kremer JM, Koff R: A debate: should patients with rheumatoid arthritis on methotrexate undergo liver biopsies? Semin Arthritis Rheum 1992, 21: 376\u2013386. 10.1016\/0049-0172(92)90038-F","journal-title":"Semin Arthritis Rheum"},{"key":"59_CR17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1155\/1996\/213596","volume":"10","author":"DA Malatjalian","year":"1996","unstructured":"Malatjalian DA, Ross JB, Williams CN, Colwell SJ, Eastwood BJ: Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can J Gastroenterol 1996, 10: 369\u2013375.","journal-title":"Can J Gastroenterol"},{"key":"59_CR18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/1523-1747.ep12500067","volume":"79","author":"RE Ashton","year":"1982","unstructured":"Ashton RE, Millward-Sadler GH, White JE: Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis. J Invest Dermatol 1982, 79: 229\u2013232. 10.1111\/1523-1747.ep12500067","journal-title":"J Invest Dermatol"},{"key":"59_CR19","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/j.1365-2133.1994.tb02901.x","volume":"130","author":"RJ Van Dooren-Greebe","year":"1994","unstructured":"Van Dooren-Greebe RJ, Kuijpers AL, Mulder J, De Boo T, Van de Kerkhof PC: Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 1994, 130: 204\u2013210.","journal-title":"Br J Dermatol"},{"key":"59_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/BF01308193","volume":"30","author":"SB Lanse","year":"1985","unstructured":"Lanse SB, Arnold GL, Gowans JD, Kaplan MM: Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis. An acceptable risk\/benefit ratio. Dig Dis Sci 1985, 30: 104\u2013109. 10.1007\/BF01308193","journal-title":"Dig Dis Sci"},{"key":"59_CR21","first-page":"197","volume":"3","author":"S Kevat","year":"1988","unstructured":"Kevat S, Ahern M, Hall P: Hepatotoxicity of methotrexate in rheumatic diseases. Med Toxicol Adverse Drug Exp 1988, 3: 197\u2013208.","journal-title":"Med Toxicol Adverse Drug Exp"},{"key":"59_CR22","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/j.1365-2133.1994.tb08596.x","volume":"131","author":"OM Dolan","year":"1994","unstructured":"Dolan OM, Burrows D, Irvine A, Walsh M: The value of a baseline liver biopsy prior to methotrexate treatment. Br J Dermatol 1994, 131: 891\u2013894.","journal-title":"Br J Dermatol"},{"key":"59_CR23","volume-title":"Guidelines on the use of liver biopsy in clinical practice","author":"British Society of Gastroenterology","year":"2004","unstructured":"British Society of Gastroenterology: Guidelines on the use of liver biopsy in clinical practice. 2004."},{"key":"59_CR24","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/j.1365-2133.1987.tb05867.x","volume":"116","author":"IH Coulson","year":"1987","unstructured":"Coulson IH, McKenzie J, Neild VS, Joseph AE, Marsden RA: A comparison of liver ultrasound with liver biopsy histology in psoriatics receiving long-term methotrexate therapy. Br J Dermatol 1987, 116: 491\u2013495.","journal-title":"Br J Dermatol"},{"key":"59_CR25","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/0190-9622(91)70173-Y","volume":"25","author":"H Zachariae","year":"1991","unstructured":"Zachariae H, Aslam HM, Bjerring P, Sogaard H, Zachariae E, Heickendorff L: Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis. J Am Acad Dermatol 1991, 25: 50\u201353.","journal-title":"J Am Acad Dermatol"},{"key":"59_CR26","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/j.1365-2133.1996.tb03827.x","volume":"135","author":"MJ Boffa","year":"1996","unstructured":"Boffa MJ, Smith A, Chalmers RJ, Mitchell DM, Rowan B, Warnes TW, Shomaf M, Haboubi NY: Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients. Br J Dermatol 1996, 135: 538\u2013544. 10.1046\/j.1365-2133.1996.d01-1036.x","journal-title":"Br J Dermatol"},{"key":"59_CR27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1046\/j.1365-2133.2001.03959.x","volume":"144","author":"H Zachariae","year":"2001","unstructured":"Zachariae H, Heickendorff L, Sogaard H: The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up. Br J Dermatol 2001, 144: 100\u2013103. 10.1046\/j.1365-2133.2001.03959.x","journal-title":"Br J Dermatol"},{"key":"59_CR28","first-page":"274","volume-title":"Cells of the hepatic sinusoid","author":"Mathew J","year":"1993","unstructured":"Mathew J, Burt AD: Cellular mechanisms of fibrogenesis in genetic haemochromatosis. In Cells of the hepatic sinusoid. Volume 4. Edited by: Knook DL and Wisse E. , The Kupffer Cell Foundation, Netherlands; 1993:274\u2013276."},{"key":"59_CR29","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1155\/2002\/161569","volume":"16","author":"A PC","year":"2002","unstructured":"Wojcik JP, Speechley MR, Kertesz AE, Chakrabarti S, PC A: Natural history of C282Y homozygotes for hemochromatosis. Can J Gastroenterol 2002, 16: 297\u2013302.","journal-title":"Can J Gastroenterol"},{"key":"59_CR30","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0168-8278(03)00078-3","volume":"38","author":"SG Hubscher","year":"2003","unstructured":"Hubscher SG: Iron overload, inflammation and fibrosis in genetic haemochromatosis. J Hepatol 2003, 38: 521\u2013525. 10.1016\/S0168-8278(03)00078-3","journal-title":"J Hepatol"},{"key":"59_CR31","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S0002-9343(05)80060-9","volume":"90","author":"QE Whiting-O'Keefe","year":"1991","unstructured":"Whiting-O'Keefe QE, Fye KH, Sack KD: Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991, 90: 711\u2013716.","journal-title":"Am J Med"},{"key":"59_CR32","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1159\/000246408","volume":"192","author":"H Zachariae","year":"1996","unstructured":"Zachariae H, Sogaard H, Heickendorff L: Methotrexate-induced liver cirrhosis. Clinical, histological and serological studies--a further 10-year follow-up. Dermatology 1996, 192: 343\u2013346.","journal-title":"Dermatology"}],"container-title":["BMC Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-5945-5-12.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-5945-5-12\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-5945-5-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-5945-5-12.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T21:20:08Z","timestamp":1630444808000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcdermatol.biomedcentral.com\/articles\/10.1186\/1471-5945-5-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,29]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["59"],"URL":"https:\/\/doi.org\/10.1186\/1471-5945-5-12","relation":{},"ISSN":["1471-5945"],"issn-type":[{"value":"1471-5945","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11,29]]},"assertion":[{"value":"11 June 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"12"}}